

## Electronic supplementary material

**ESM Table 1** Summary of treatment-emergent adverse events (safety population)

Event	Insulin glargine ( <i>n</i> =514)	NPH insulin ( <i>n</i> =503)
Any event	490 (95.3)	479 (95.2)
Patients with any treatment-emergent serious adverse event	211 (41.1)	215 (42.7)
Patients permanently discontinued due to treatment-emergent adverse event	16 (3.1)	11 (2.2)
Treatment-emergent adverse event leading to death	14 (2.7)	11 (2.2)

Data are *n* (%)